Evidence map›Paper›PMID 42464296›Full record

ReviewJournal of nanobiotechnology2026

Advanced herbal self-assembled nanoplatforms: targeted, stimuli-responsive, and precision therapeutics for human diseases.

Xiao Zou, Jianxin Liu, Xuecong Ren, Yuxin Hu, Qian Feng, Jianing Mi, Xiaogang Zhou, Jianming Wu, Jing Wei, Anguo Wu

Abstract readReview
In one paragraph

Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiao Zou *Department of Pharmacy, Chengdu Wenjiang District People's Hospital, Chengdu, 611130, China.
Jianxin Liu *School of Pharmaceutical Sciences, Sino-Pakistan Center On Traditional Chinese Medicine, China-Pakistan International Science and Technology Innovation Cooperation Base for Ethnic Medicine Development in Hunan Province, Hunan University of Medicine, Huaihua, 418000, China.
Xuecong Ren *Department of Geriatrics, Zhejiang Key Laboratory of Traditional Chinese Medicine for the Prevention and Treatment of Senile Chronic Diseases, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, 310005, China.
Yuxin Hu *Luzhou Key Laboratory of Bioactivity Screening and Drugability Evaluation of Traditional Chinese Medicine, Key Laboratory of Medical Electrophysiology of Ministry of Education, School of Pharmacy, Southwest Medical University, Luzhou, 646000, China.
Qian Feng *Luzhou Key Laboratory of Bioactivity Screening and Drugability Evaluation of Traditional Chinese Medicine, Key Laboratory of Medical Electrophysiology of Ministry of Education, School of Pharmacy, Southwest Medical University, Luzhou, 646000, China.
Jianing MiState Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong, China.
Xiaogang ZhouLuzhou Key Laboratory of Bioactivity Screening and Drugability Evaluation of Traditional Chinese Medicine, Key Laboratory of Medical Electrophysiology of Ministry of Education, School of Pharmacy, Southwest Medical University, Luzhou, 646000, China.
Jianming WuLuzhou Key Laboratory of Bioactivity Screening and Drugability Evaluation of Traditional Chinese Medicine, Key Laboratory of Medical Electrophysiology of Ministry of Education, School of Pharmacy, Southwest Medical University, Luzhou, 646000, China. jianmingwu@swmu.edu.cn.
Jing WeiDepartment of Ophthalmology, the Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China. weijingzhuzhu@swmu.edu.cn.
Anguo WuLuzhou Key Laboratory of Bioactivity Screening and Drugability Evaluation of Traditional Chinese Medicine, Key Laboratory of Medical Electrophysiology of Ministry of Education, School of Pharmacy, Southwest Medical University, Luzhou, 646000, China. wuanguo1114@swmu.edu.cn.

Funding

Foundation of Institute of Traditional Chinese Medicine Health Industry, China Academy of Chinese Medical Sciences ZYTS-2025011Joint Project of Luzhou Municipal People's Government and Southwest Medical University 2024LZXNYDJ026Natural Science Foundation of China 81903829Open Fund of Innovation Center for Basic Research on Metabolic Cardiovascular Diseases, Southwest Medical University xnykdxcxzx-2025-10Open Project from the State Key Laboratory of Traditional Chinese Medicine Syndrome SKLKY2024B0006Ziyang Central Hospital - Southwest Medical University Science and Technology Strategic Cooperation 2025ZYXNYD13
6 · The paper itself

Abstract

Herbal self-assembled nanoplatforms (H-SANs) represent an emerging strategy in herbal nanomedicine by integrating the intrinsic bioactivity of phytochemicals with supramolecular nanoscale organization. Unlike conventional nanocarriers that may be limited by low drug loading, excipient burden, premature release, and scale-up complexity, H-SANs are carrier-free or predominantly bioactive systems formed through noncovalent interactions, including π-π stacking, hydrogen bonding, hydrophobic forces, electrostatic interactions, and metal coordination, among polyphenols, flavonoids, alkaloids, terpenoids, saponins, and related phytochemical components. Reported assemblies can achieve high drug loading, exhibit stimuli-responsive structural changes under disease-associated cues such as acidic pH, redox imbalance, or enzyme overexpression, and can be further engineered with targeting motifs. Preclinical studies have explored their applications in oncology, inflammation, neurodegeneration, metabolic disorders, cardiovascular disease, antimicrobial therapy, wound repair, kidney injury, and bone disorders, where H-SANs may act as bioactive scaffolds as well as delivery systems. However, their translational development remains constrained by dilution-dependent instability, incomplete understanding of in vivo disassembly and parent-drug regeneration, protein corona formation, tumor transport heterogeneity, raw-material variability, manufacturing reproducibility, regulatory classification, and limited human-relevant pharmacokinetic and safety evidence. Emerging strategies, including AI-assisted modeling, rational multicomponent co-assembly, continuous manufacturing, and improved biological validation, may help address these challenges. Overall, H-SANs provide a promising but still largely preclinical framework for high-payload herbal nanomedicine, and their clinical value will require rigorous physicochemical characterization, reproducible manufacturing, and cautious translational validation.

Indexed as

PhytochemicalsPrecision MedicineAnimalsDrug Delivery SystemsHumansNanomedicinePhytochemicalsHerbal self-assembled nanoplatformsNoncovalent interactionsStimuli-responsive deliveryTargeted therapeuticsTherapeutic applications

Identifiers

PMID42464296
PMCPMC13656476

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.